Patients with advanced non‑small cell lung cancer with EGFR mutations in addition to complex mutations treated with osimertinib have a poor clinical outcome: A real‑world data analysis
Kaplan-Meier survival analysis of patients with NSCLC with or without... | Download Scientific Diagram
Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study - JTO Clinical and Research Reports
The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer | Scientific Reports
Kaplan-Meier PFS (A) and OS (B) curves for the all NSCLC patients... | Download Scientific Diagram
Cancers | Free Full-Text | A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals Distinct Survival Patterns Based on EGFR Mutation Subclasses
Critical Review of *EGFR*-Mutated NSCLC What We Do and Do Not Know | Published in healthbook TIMES Oncology Hematology
Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions | Scientific Reports
Structure-based classification predicts drug response in EGFR-mutant NSCLC | Nature
The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study | Scientific Reports
Kaplan-Meier curves for overall survival of lung adenocarcinoma... | Download Scientific Diagram
Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients? | BMC Cancer | Full Text
A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes | SpringerLink
Cytoplasmic ERβ1 expression is associated with survival of patients with Stage IV lung adenocarcinoma and an EGFR mutation at exon 21 L858R subsequent to treatment with EGFR‑TKIs
Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients? | BMC Cancer | Full Text
Frontiers | Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
Treatment Options for Non-Small Cell Lung Cancer Harboring Uncommon *EGFR* Mutations | Published in healthbook TIMES Oncology Hematology
The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis | Scientific Reports
An exon 21 L858R EGFR mutation is associated with a decreased survival... | Download Scientific Diagram
THE LIVES AFFECTED BY EGFR EXON 20 INSERTION MUTATIONS
10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient | European Respiratory Society
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC | NEJM
Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program - ScienceDirect
Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort - ScienceDirect
Overall survival in patients with EGFR exon 20 insertions and major... | Download Scientific Diagram
